Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis

Condition:   Histiocytosis Intervention:   Drug: Vemurafenib Sponsors:   Anna Raciborska;   Maria Sklodowska-Curie Institute - Oncology Center;   Łukasiewicz Research Network;   Wrocław University of Environmental and Life Sciences Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials